Back to News
Market Impact: 0.42

Avista Q1 2026 slides: earnings beat forecast despite revenue miss

AVA
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsInfrastructure & DefenseRegulation & LegislationBanking & Liquidity
Avista Q1 2026 slides: earnings beat forecast despite revenue miss

Avista beat Q1 2026 EPS expectations at $1.11 versus $1.05 consensus, though revenue missed sharply at $555 million, down about 8% year over year and 15.6% below estimates. The company reaffirmed full-year non-GAAP utility EPS guidance of $2.52 to $2.72 and outlined a $3.44 billion base capex plan for 2026-2030, supporting long-term rate base growth of 6%-7% CAGR. Liquidity remains manageable at $156 million, with $230 million of planned long-term debt issuance and $90 million of additional equity expected in 2026.

Analysis

AVA is signaling a classic regulated-utility setup where earnings quality is improving faster than top-line optics suggest. The key second-order takeaway is that margin recovery plus expense discipline can mask weak load/revenue until rate cases and capital deployment catch up, which is why the stock can stay bid even on a revenue miss. The market is effectively pricing the next leg of growth as a balance-sheet and regulatory story, not an operating-volume story. The biggest winner from this plan is likely the capital base itself: transmission/distribution and grid-hardening spend should translate into a cleaner rate-base growth profile, and that tends to favor contractors, equipment vendors, and regulated peers with similar capex runways. The flip side is that the more AVA leans into a large-load/customer and Washington’s long rate-plan construct, the more earnings become exposed to regulatory timing risk rather than demand risk. In other words, the near-term catalyst is not weather; it’s whether commissions allow recovery on time and on the full invested capital base. The consensus may be underestimating how much financing requirements matter here. With a meaningful equity raise still ahead, the stock can re-rate higher on guidance stability, but that also caps upside if rates back up or equity issuance is delayed into a weaker tape. Over a 6-12 month window, the main tail risk is a benign operating year that paradoxically slows the narrative because the market has already moved to price in 6-7% rate-base growth; any miss on execution or regulatory cadence could compress the multiple quickly. Contrarian view: after a very large move, this is less a clean value story and more a duration trade on regulated compounding. The stock likely deserves a premium if management can keep capital deployment and recovery on schedule, but the asymmetry now sits in execution slippage, not earnings disappointment. If the Street is extrapolating steady multiple expansion from one strong quarter, that may be too linear for a name with financing, rate-case, and weather sensitivity embedded.